# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and assigns a Buy rating with a ...
Barclays analyst Matt Miksic maintains Alphatec Holdings (NASDAQ:ATEC) with a Overweight and raises the price target from $2...
Canaccord Genuity analyst Caitlin Cronin maintains Alphatec Holdings (NASDAQ:ATEC) with a Buy and maintains $20 price target.
Alphatec Holdings (NASDAQ:ATEC) raises FY2025 sales outlook from $734.000 million to $742.000 million vs $734.219 million estim...
Alphatec Holdings (NASDAQ:ATEC) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0...